Adial Pharmaceuticals Inc (ADIL) — Cash Flow-to-Debt Ratio
Adial Pharmaceuticals Inc (ADIL) has a Cash Flow-to-Debt Ratio of -1.07x as of March 2026, meaning its operating cash flow of $-1.61 Million could theoretically repay -1% of its total liabilities ($1.51 Million) in one year. Explore investment intensity of Adial Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Adial Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Adial Pharmaceuticals Inc across 11 annual periods. Also explore ADIL total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Adial Pharmaceuticals Inc (2015–2025)
Year-by-year debt coverage analysis for Adial Pharmaceuticals Inc. For market capitalisation and broader financial context, see market cap of Adial Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.27x | $-6.49 Million | $1.52 Million | ▲ +39.9% |
| 2024 | -7.09x | $-6.92 Million | $975.86K | ▲ +31.9% |
| 2023 | -10.42x | $-6.81 Million | $653.51K | ▼ -128.7% |
| 2022 | -4.55x | $-11.19 Million | $2.46 Million | ▼ -57.2% |
| 2021 | -2.90x | $-11.95 Million | $4.13 Million | ▲ +42.9% |
| 2020 | -5.07x | $-7.63 Million | $1.51 Million | ▲ +56.9% |
| 2019 | -11.76x | $-6.34 Million | $539.05K | ▼ -21.4% |
| 2018 | -9.68x | $-2.50 Million | $257.97K | ▼ -1919.9% |
| 2017 | -0.48x | $-494.86K | $1.03 Million | ▲ +55.4% |
| 2016 | -1.08x | $-274.38K | $255.02K | ▲ +87.7% |
| 2015 | -8.76x | $-465.22K | $53.08K | — |